Open-label phase 3b clinical study to evaluate the immunogenicity and safety of FSME-IMMUN 0.5 ml with the first and second vaccination being administered according to a rapid immunization schedule in healthy adults aged 16 years or older

Trial Profile

Open-label phase 3b clinical study to evaluate the immunogenicity and safety of FSME-IMMUN 0.5 ml with the first and second vaccination being administered according to a rapid immunization schedule in healthy adults aged 16 years or older

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Baxter Healthcare Corporation; Pfizer
  • Most Recent Events

    • 12 Oct 2012 Trial status is active, no longer recruiting as reported by ClinicalTrials.gov (Extension study: NCT01582698).
    • 12 Oct 2012 Trial status is active, no longer recruiting as reported by ClinicalTrials.gov (Extension study: NCT01582698).
    • 12 Oct 2012 Trial status is active, no longer recruiting as reported by ClinicalTrials.gov (Extension study: NCT01582698).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top